Virginia GLP-1 & Weight Loss Med Spa Compliance (2026)

Semaglutide and tirzepatide reshaped the Virginia aesthetics market faster than any treatment since neurotoxin — and a GLP-1 program is the med spa service most likely to draw a regulator's attention here, because it is the only one that engages all three of the Commonwealth's health-licensing boards at once: the Board of Medicine, the Board of Nursing, and the Board of Pharmacy. Each can act on its own.

This is the Virginia companion to our national GLP-1 med spa compliance guide, which covers the federal layer we won't repeat here. What follows is the Commonwealth's overlay: the prescriber hierarchy, the Schedule VI wrinkle that pulls the Board of Pharmacy into your supply chain, Virginia's four-element relationship test, the weight-loss rule the Board of Medicine quietly deleted in 2025, and the documentation that keeps a program defensible.

Why a Virginia GLP-1 Program Answers to Three Boards

Virginia never enacted a med spa statute — no such license, no facility inspection regime, no dedicated chapter of the Administrative Code. That absence is routinely misread as latitude. It is the opposite: with no purpose-built framework, a weight-loss program is governed by the general professional statutes, and three boards apply them to the same facts.

The Virginia Board of Medicine

The Board of Medicine licenses physicians, PAs, and — jointly with the Board of Nursing — nurse practitioners, and it owns the definition of the practice of medicine. Va. Code 54.1-2901 sets out who is exempt from licensure and on what terms; Va. Code 54.1-2902 makes practicing without the required license unlawful. Writing a GLP-1 prescription is diagnosis and treatment, so the Board's rules on delegation, examination, records, and unprofessional conduct attach from the first patient.

The Virginia Board of Nursing

The Board of Nursing licenses RNs, LPNs, and advanced practice registered nurses. It decides when a nurse practitioner may prescribe under a practice agreement and when the Commonwealth grants autonomous practice under 18VAC90-30-86. It also sets the outer edge of what an RN may do on a prescriber's order — which, in most Virginia weight-loss clinics, describes the person holding the syringe.

The Virginia Board of Pharmacy

The Board of Pharmacy regulates the drug: how it is compounded, dispensed, labeled, and shipped into the Commonwealth. It is the most operationally dangerous of the three, because a program can be flawless on prescribing and still be buying product from a pharmacy that should not be making it. Va. Code 54.1-3434.1 requires any out-of-state pharmacy shipping Schedule II through VI drugs into Virginia to register — which brings us to the wrinkle most operators miss.

The Schedule VI Wrinkle: Semaglutide Is a Scheduled Drug in Virginia

Virginia's Drug Control Act contains a schedule the federal Controlled Substances Act does not. Va. Code 54.1-3455 defines Schedule VI to include any drug federal law requires to bear the "Rx only" legend that has not been placed in Schedules I through V — essentially every prescription drug that is not federally controlled.

Semaglutide, tirzepatide, and liraglutide are all Schedule VI here. That does not make them controlled substances in the DEA sense — no registration, no PDMP reporting, no federal in-person prescribing rule — but it does pull them inside the Drug Control Act. Your nonresident pharmacy partner must be Virginia-registered, your recordkeeping obligations are statutory, and Va. Code 54.1-3408 governs who may administer the drug.

Who Can Prescribe GLP-1 Medications at a Virginia Med Spa

Prescriptive authority is the first question, and each tier has conditions attached.

Physicians (MD or DO)

A physician licensed by the Board of Medicine holds full prescriptive authority and may initiate, titrate, and discontinue GLP-1 therapy after an appropriate evaluation. The physician is also the anchor of everything below: practice agreements, standing orders, protocol approval, and chart review all run back to a physician unless every prescriber holds autonomous authority.

Nurse Practitioners: Practice Agreement or Autonomous Practice

Virginia is a two-track state for nurse practitioners, and which track your NP is on changes the whole program's structure. An NP without autonomous designation must work in collaboration and consultation with a patient care team physician under a written practice agreement, per 18VAC90-30-120. The agreement must describe the NP's prescriptive authority — and for a weight-loss program it should name GLP-1 initiation, titration, and discontinuation explicitly rather than leaning on a generic scope clause.

An NP who qualifies under 18VAC90-30-86 may be granted an autonomous practice designation and prescribe with no practice agreement and no patient care team physician at all. Since July 1, 2024 the threshold has been three years of full-time equivalent clinical experience — roughly 4,500 hours — down from five, a change made by HB 971 and reflected in Va. Code 54.1-2957. A med spa staffed by an experienced autonomous NP can therefore run a GLP-1 program with no collaborating physician. Verify the designation on the Board of Nursing's license lookup; it is granted, not self-declared.

Physician Assistants and What HB 746 Will Change

A PA prescribes under a practice agreement governed by Va. Code 54.1-2952 and 18VAC85-50-101, which must set out the acts the PA performs, provide for periodic review of patient charts, and address collaboration, consultation, complex cases, emergencies, and referrals.

HB 746 (Chapter 418), signed April 8, 2026, will let a PA with at least three years of full-time clinical experience practice without a written agreement, on an attestation from a patient care team physician. It is a genuine change, but not yet operative: the Board of Medicine must first adopt implementing regulations. Until then, a Virginia PA prescribing GLP-1s still needs a current, signed practice agreement.

Who Cannot Prescribe

Registered nurses, LPNs, medical assistants, estheticians, health coaches, and non-clinical owners cannot prescribe GLP-1 medications in Virginia — no protocol workaround exists. A non-prescriber who screens intake forms and "approves" patients, or an owner who decides who gets the drug, is practicing medicine unlawfully under Va. Code 54.1-2902. The full role-by-role scope breakdown is in who can inject Botox in Virginia.

Virginia's Good-Faith Exam: The Bona Fide Practitioner-Patient Relationship

Other states talk about a "good-faith exam." Virginia codifies it — in the pharmacy chapter, which is why operators reading only the Board of Medicine's regulations miss it.

The Four Elements of Va. Code 54.1-3303

Va. Code 54.1-3303 provides that a prescription must be issued for a medicinal or therapeutic purpose within a bona fide practitioner-patient relationship. To establish that relationship, the practitioner must:

1. Ensure a medical or drug history is obtained — an actual history, reviewable, not a checkbox
2. Provide information to the patient about the benefits and risks of the drug being prescribed
3. Perform or have performed an appropriate examination of the patient, either physically or through instrumentation and diagnostic equipment by which images and medical records may be transmitted electronically
4. Initiate additional interventions and follow-up care if necessary, especially where a prescribed drug may have serious side effects

Read element four alongside a GLP-1's label. These drugs carry a boxed warning for thyroid C-cell tumors, so "serious side effects" is not a hypothetical qualifier: follow-up is part of what makes the original prescription lawful.

What to Document at the Initial Evaluation

Virginia publishes no GLP-1-specific intake form, so the chart must show the four elements were satisfied. A defensible evaluation records:

• Measured anthropometrics — height, weight, and BMI taken by the practice, not self-reported
• Medical, surgical, and weight history — prior attempts, current medications, allergies
• Comorbidities establishing medical necessity — diabetes, prediabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease
• Contraindication screen — medullary thyroid carcinoma or MEN-2 history, pancreatitis, gastroparesis, pregnancy, significant renal or hepatic impairment
• Laboratory review where indicated — metabolic panel, A1c, thyroid function
• Risk-benefit discussion and informed consent, including the boxed warning and any off-label use
• A written treatment plan — starting dose, titration, monitoring cadence, discontinuation criteria

The evaluation is a prescriber act. Support staff may collect intake data and prepare the chart, but the clinical judgment establishing the relationship belongs to whoever signs the prescription.

The Rule Virginia Deleted: 18VAC85-20-90 and What Replaced It

Here is the Virginia development most operators have not caught, and it cuts both ways.

What the Repealed Rule Required

For years the Board of Medicine maintained 18VAC85-20-90, "Pharmacotherapy for weight loss," which barred prescribing Schedule III through VI drugs for weight reduction unless specific conditions were met: a history and physical recorded at initiation; review of laboratory work as indicated, including thyroid function; an electrocardiogram within 90 days of initial prescribing where the drug could adversely affect cardiac function; a recorded diet and exercise program; and a patient visit within the first 30 days. A parallel provision for PAs sat at 18VAC85-50-181. Because Virginia's Schedule VI sweeps in every "Rx only" drug, that rule reached GLP-1s directly — a state-mandated monitoring schedule in all but name.

What Changed, and What Governs Now

The Board repealed 18VAC85-20-90 effective February 27, 2025 (Virginia Register Vol. 41, Issue 11) during a periodic review, and the PA counterpart at 18VAC85-50-181 was repealed effective July 17, 2025. Nothing replaced them.

The tempting misreading is that Virginia deregulated weight-loss prescribing. It did not. What disappeared was a checklist; what remains is the standard of care, enforced through Va. Code 54.1-3303 and the Board's unprofessional-conduct authority. A prescriber can no longer point to a regulation and say "I did the four things it listed" — the monitoring plan now has to be justified on clinical grounds, a higher bar in a contested case, not a lower one. Keep doing what the repealed rule required and write it into your protocol; running looser than a standard Virginia retired eighteen months ago is a poor bet.

Can a Nurse Administer GLP-1 Injections in Virginia?

In most Virginia clinics the prescriber is not the person giving the injection. That handoff is lawful — within firm limits.

What a Registered Nurse May Do

A Virginia RN may administer a GLP-1 injection a prescriber has already ordered for a specific patient, perform follow-up weight and vitals checks, educate the patient, and document the encounter. The authority runs through the exceptions in Va. Code 54.1-2901, which let a licensed nurse act on a practitioner's order, together with the practice's written protocols and the Board of Nursing's scope rules. The prescriber need not be physically present — but the order must exist, and it must be patient-specific.

What the Order and Protocol Must Contain

• A patient-specific order from the prescriber who performed the evaluation and established the bona fide relationship
• Drug-specific written protocols naming the medication, eligible population, dose ranges, and when the RN may or may not proceed
• Dated before first use, reviewed on a stated schedule, with the medical director's signature on the current version
• Escalation and emergency criteria, and training and competency documentation for each administering nurse

Where the Line Falls: LPNs, Medical Assistants, and Unlicensed Staff

An RN may not establish the relationship, diagnose, select a patient, or choose the drug or dose. A "standing order" that lets a nurse clear weight-loss intakes without an individualized prescriber evaluation is unlicensed prescribing — the failure mode Virginia enforcement is likeliest to find in a telehealth-heavy program.

LPNs work under narrower authority. Unlicensed personnel occupy the strictest position: Va. Code 54.1-3408 permits an unlicensed person to administer a drug only under the direct and immediate supervision of the practitioner — in practice, the prescriber in the building rather than on the phone. An esthetics license grants nothing here; Va. Code 54.1-700 excludes the practice of medicine from esthetics.

Compounded Semaglutide and Tirzepatide Sourcing in Virginia

Sourcing is where Virginia programs are most exposed, because the model that built thousands of weight-loss clinics rested on a federal exemption that no longer exists.

The Federal Baseline: The Shortage Era Is Over

Section 503A of the federal Food, Drug, and Cosmetic Act permits a state-licensed pharmacy to compound for an individual patient; Section 503B covers outsourcing facilities. During a declared shortage, compounders could copy an FDA-approved drug. That window has closed. The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025; the grace periods ran out during 2025, and the litigation challenging those determinations failed to win injunctive relief. What each facility type may still legally do is broken out in our 503A versus 503B compounded GLP-1 sourcing guide.

What survives is narrow: compounding on a documented, patient-specific clinical need — a genuine allergy to an inactive ingredient, or a dosage form the manufacturer does not make. Not a preference, not a price difference.

Virginia's Own Compounding Limits

Va. Code 54.1-3410.2 and 18VAC110-20-321 require compounding to follow USP-NF standards, and constrain two practices GLP-1 clinics lean on:

• Anticipatory compounding is permitted only based on a routine, regularly observed prescribing pattern — not speculative production for a marketing push
• Office-use supply to a practitioner is limited to a reasonable amount, administered by the practitioner personally or under direct and immediate supervision, and only where there is a critical need to treat an emergency condition or as federal law otherwise allows

A routine weight-loss program is not an emergency condition. A med spa that orders bulk compounded semaglutide "for the practice" breaches the federal patient-specific requirement and Virginia's office-use limit at once.

The Nonresident Pharmacy Requirement Most Practices Skip

Because GLP-1s are Schedule VI drugs here, Va. Code 54.1-3434.1 applies: any pharmacy outside the Commonwealth shipping Schedule II through VI drugs into Virginia on a prescription must register with the Board, and registration requires a current inspection report showing USP-NF compliance. If your product arrives from an out-of-state compounder, checking that registration on the Board's license lookup is the highest-yield diligence available to a Virginia operator.

What a Virginia Program Should Source

The defensible default is the FDA-approved branded product — semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and liraglutide (Saxenda) — dispensed by a Virginia-licensed or registered nonresident pharmacy on a valid prescription. Where a clinical exception genuinely applies, keep the patient-specific justification in the chart and the pharmacy's registration on file. Oral formulations follow the same logic, covered in our post on oral GLP-1 options for med spas.

Telehealth Prescribing for Weight Loss in Virginia

Telehealth is how most weight-loss programs run, and Virginia permits it for GLP-1s. The limits repay close reading: the statute is unusually specific about what counts.

Telehealth Is Allowed — No Prior In-Person Exam Required

GLP-1 receptor agonists are not federally controlled substances, so the DEA framework for telemedicine prescribing of controlled drugs does not apply. Under Va. Code 54.1-3303, a prescriber may establish the bona fide relationship by face-to-face interactive, two-way, real-time communications services or store-and-forward technologies with no prior in-person examination, provided the statutory conditions are met: a medical history available for review; an updated history at the time of prescribing; a diagnosis made at the time of prescribing; and conformity to the standard of care expected of in-person care, including examination and diagnostic testing where that standard requires them.

The Same Standard of Care Applies

The Board of Medicine's telemedicine guidance is unambiguous: a Virginia patient is entitled to the same standard of care by video as in the room. The contraindication screen, risk-benefit discussion, treatment plan, and follow-up all have to happen and be charted.

The hard limit is what Virginia excludes from telemedicine in the first place: an audio-only phone call, an email, a fax, and — decisively for this industry — an online questionnaire. A patient who fills out a web form and receives a prescription has not been in a telemedicine encounter under Virginia law, so no bona fide relationship was established and the prescription was not validly issued. Every questionnaire-to-shipment funnel operating into Virginia has this problem.

A Virginia Telehealth Checklist for GLP-1

• Virginia-licensed prescriber with current authority and, for an NP, an agreement or autonomous designation
• Synchronous, interactive encounter for the initial evaluation — not a form, not a phone call alone
• Updated history at the time of prescribing, with the prior history available for review
• A diagnosis made and recorded at the time of prescribing, not backfilled
• An in-person referral pathway where the standard of care needs an exam the platform cannot deliver
• Prescriber contact information on the prescription, per Board of Medicine guidance
• Documented follow-up scheduled before the encounter ends

Monitoring a Virginia GLP-1 Program

With 18VAC85-20-90 gone, the monitoring schedule is something your practice writes and defends rather than something the Commonwealth hands you — which makes getting it on paper more important, not less.

Baseline Before the First Dose

At initiation, verify measured BMI and comorbidities, screen contraindications against the label, reconcile medications, and order baseline labs where indicated — a metabolic panel and A1c at minimum, with thyroid function and lipid or hepatic studies as the presentation warrants. The repealed rule named thyroid testing specifically; given this class's boxed warning, that remains the sensible default.

The Titration Window

Schedule the first structured follow-up within 30 days of initiation — the interval Virginia's own rule required until 2025 — then review every four to twelve weeks through dose escalation, recording weight, blood pressure, tolerability, and adverse events. Treat each dose change as a documented clinical decision, not an automatic step. A ready-built cadence is laid out in our GLP-1 monitoring schedule template.

Adverse-Event Vigilance and Discontinuation

Screen at every encounter for persistent gastrointestinal symptoms, signs of pancreatitis, gallbladder disease, and thyroid symptoms. Define in advance what triggers a hold, a dose reduction, or discontinuation, and record the reasoning. An adverse-event log is the clearest evidence a program is actively managed rather than on autopilot.

Documentation a Virginia GLP-1 Program Must Keep

Documentation is the through-line across all three boards. In an investigation, a Virginia regulator's working assumption is that what is not written down did not happen.

Structural and Clinical Records

• A written GLP-1 protocol signed and dated by the medical director — eligibility, contraindications, titration, monitoring, discontinuation criteria
• Current practice agreements for every non-autonomous NP and every PA, expressly covering weight-management prescribing
• Autonomous practice verification for any NP prescribing without an agreement
• RN protocols and standing orders, drug-specific and dated before first use, plus per-nurse competency records
• Per-patient charts capturing all four elements of Va. Code 54.1-3303, plus consent, BMI, and every dose decision

Virginia's Six-Year Retention Rule

The Board of Medicine requires patient records to be kept a minimum of six years after the last encounter, and 18VAC85-20-26 obliges the practitioner to notify patients how records may be obtained and what the retention policy is. For a program whose patients start, stop, and restart therapy, decide early how "last encounter" is calculated and write the answer into your records policy rather than reconstructing it under subpoena.

Quality-Assurance and Sourcing Records

Oversight has to be visible to be credible: documented chart review on a stated cadence, QA meetings with minutes, an adverse-event log, and evidence of corrective action. On the pharmacy side, keep the dispensing pharmacy's Virginia licensure or nonresident registration on file, retain the justification for any compounded product, and be able to trace a vial to a lawful source. If you would rather not draft this stack from scratch, our ready-to-use med spa compliance SOPs supply the policy layer behind every item on this list.

Does a Virginia Med Spa Need a Medical Director for GLP-1?

Virginia's answer is more nuanced than most states', and worth understanding before signing a physician to a monthly retainer.

The Narrow Case Where the Answer Is No

No Virginia statute requires a med spa to have a medical director, and an NP with autonomous designation prescribes with no patient care team physician at all. A practice whose only prescriber is an autonomous NP, whose injections are given by RNs on that NP's patient-specific orders, and whose protocols the NP writes and reviews, can be structurally complete without a physician — a real and underused option in the Commonwealth.

Why Most Programs Still Need One

Everything else pulls a physician back in. A non-autonomous NP needs a patient care team physician and a practice agreement; a PA needs one until HB 746's regulations take effect. And if the practice is owned by a professional corporation, Va. Code 13.1-543 restricts ownership to individuals licensed to render the same service. Virginia has no blanket corporate practice of medicine statute of the kind California and New York enforce, but Va. Code 54.1-2902 makes unlicensed practice unlawful, and a lay owner directing which patients receive therapy has crossed that line however the entity is papered.

Where a physician is in the structure, the role is substantive: approving the protocol and standing orders, signing and reviewing agreements, running chart review, and staying reachable. The box-by-box view of oversight, ownership, records, and consent is in the Virginia med spa compliance checklist.

The Rented-Signature Trap

A physician paid to appear on the paperwork who never reviews a chart and cannot be reached is a liability to the practice and to their own license. Virginia's practice agreement regulations require periodic chart review and physician input in complex cases and emergencies — auditable obligations. Govern the arrangement with a written agreement paying fair market value for actual services, never a percentage of medical revenue.

The Risks of a Non-Compliant Virginia GLP-1 Program

Because three boards can act independently on the same facts, the downside is layered — and does not stop at a license.

Board Discipline Across Three Regulators

The Board of Medicine can discipline a physician or PA for prescribing outside the standard of care, for questionnaire-only prescribing, or for signing agreements they do not honor. The Board of Nursing can act against an NP prescribing outside an agreement or without a valid autonomous designation, and against an RN administering without a patient-specific order. The Board of Pharmacy reaches the product — an unregistered pharmacy shipping in, office-use compounding outside the emergency exception, or bulk semaglutide made without patient-specific prescriptions.

Beyond Licensure, and the Cheapest Defense

Va. Code 54.1-2902 makes the unlicensed practice of medicine a criminal matter, not merely a regulatory one, and Va. Code 54.1-111 reaches related unlawful acts including practicing beyond an authorized scope. Add civil liability if a patient is harmed, unwinding of a professional entity that was never validly owned, and payment processors that drop weight-loss merchants at the first regulatory action. The cheapest protection against all of it is a documented, properly authorized program built to the standard of care from the first patient. Every Virginia-specific guide we publish sits on the Virginia med spa compliance hub.

Building a Compliant Virginia GLP-1 Program

Here is the operational stack a Virginia weight-loss program should be able to produce on demand in 2026.

1. Prescriptive authority confirmed on paper — a physician, an NP with an agreement or verified autonomous designation, or a PA with an agreement
2. A bona fide practitioner-patient relationship for every patient, all four elements charted
3. Valid patient-specific orders behind every RN-administered injection, on protocols dated before first use
4. Defensible sourcing — FDA-approved product from a Virginia-licensed or Virginia-registered pharmacy
5. Compliant telehealth — synchronous encounters at the in-person standard of care, never a questionnaire
6. A written monitoring schedule — baseline labs, a visit inside 30 days, four-to-twelve-week reviews, an adverse-event log
7. Records that survive six years and a retention notice meeting 18VAC85-20-26
8. Documented oversight — chart review, QA minutes, and a fair-market-value medical director agreement

Do those eight things and you have a program that can withstand a look from any of the three boards. Industry organizations such as AmSpa publish useful state-level updates, and the Virginia Board of Medicine, the Virginia Board of Nursing, the Virginia Board of Pharmacy, and the FDA are the primary sources behind every rule above.

Disclaimer: This article is for educational purposes only and does not constitute legal or medical advice. Virginia's prescribing, delegation, telehealth, and pharmacy-compounding rules are complex and change frequently — HB 746's implementing regulations and the status of repealed Board of Medicine sections in particular. Verify current FDA shortage status and consult a Virginia healthcare attorney and your medical director before establishing or modifying a weight-loss program.